3-isopropoxyphenylboronic Acid As a Therapeutic Target for the Sphingosine-1-phosphate Receptor in a Rat Monocrotaline Model-inducedHypertension of the Pulmonary Arteries

Introduction: Novel therapeutic strategies are essential for enhancing outcomes in patients with idiopathic pulmonary arterial hypertension (PAH). Sphingosine 1 phosphate (S1P) inhibitors have demonstrated positive effects in preclinical models of various autoimmune disorders. The pathogenesis of PAH involves extensive pulmonary vascular remodeling, marked by an abnormal increase in smooth muscle and endothelial cell growth, ultimately resulting in vessel occlusion, though the mechanisms remain largely unknown. This research is the first to assess the effectiveness of 3-Isopropoxyphenylboronic acid, an S1P1 modulator, in comparison with macitentan, a dual endothelin receptor antagonist, in a monocrotaline-induced rat model of elevated pulmonary pressure. Methods: Various assessment methods were used, such as hemodynamic evaluations, histological examination of the right ventricle and pulmonary vessels, and analysis of circulating biomarkers. objective: The pathogenesis of PAH involves extensive pulmonary vascular remodeling, marked by an abnormal increase in smooth muscle and endothelial cell growth, ultimately resulting in vessel occlusion, though the mechanisms remain largely unknown. Results: Findings of the study demonstrated that both 3-Isopropoxyphenylboronic acid (10 mg/kg/day orally) and macitentan (10 mg/kg/day) effectively slowed the progression of PAH at both functional and structural levels. Treatment commenced on day 14 after monocrotaline injection and was maintained for 14 days. Findings from all experimental approaches indicated that the S1P1 modulator produced effects comparable to macitentan. Discussion: While the reported physiological and histological improvements suggest that 3- Isopropoxyphenylboronic acid may have therapeutic value in pulmonary arterial hypertension (PAH), the direct involvement of the S1P1 receptor has yet to be shown unequivocally. To determine the specificity of the compound's activity via S1P1 regulation, further research should include receptor binding assays, gene and protein expression assessments, and pathway-specific phosphorylation indicators. result: Findings from all experimental approaches indicated that the S1P1 modulator produced effects comparable to macitentan Conclusion: In summary, the research suggests that S1P1 inhibition reduces right ventricular hypertrophy and enhances cardiac function in the context of PAH, warranting further investigation into S1P1 modulation as a potential therapeutic target for PAH management.